TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01600742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.
Study: NCT01221103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone, ofatumumab and bendamustine
Description: * Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~* Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~* Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)
Study: NCT04455984

Intervention type: OTHER
Intervention: Date collection
Description: Retrospective data analysis

Intervention type: OTHER
Intervention: Date collection
Description: Retrospective data analysis
Study: NCT03665415

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NDGameSquad
Description: The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDGameSquad
Description: The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NDGameSquad
Description: The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
Study: NCT04243421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Soft tissue aesthetics, marginal bone level on CBCT
Study: NCT01939990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo looks like the study drug but it does not contain active ingredients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5 to 10mg per day
Study: NCT00393705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Biphasic Aspart 30/70
Description: Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro LM
Description: Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro MM
Description: Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro LM
Description: Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Study: NCT00279422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: visilizumab
Study: NCT02187874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed umbilical cord occlusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early umbilical cord occlusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study: NCT00279422

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: visilizumab
Study: NCT00402883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
Study: NCT01583530

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose Group: Belimumab IV 240 mg
Description: Belimumab IV 240 mg administered on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose Group: Belimumab SC 2 x 120 mg
Description: Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose Group: Belimumab SC 1 x 240 mg
Description: Belimumab SC 240 mg x 1 injection on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose Group: Belimumab SC 1 x 200 mg
Description: Belimumab SC 200 mg x 1 injection on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly
Description: Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
Description: Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
Study: NCT04491396

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gentle Yoga and Yogic Breathing
Description: Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB.
Study: NCT01859936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
Study: NCT00772148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP -Tacro
Description: LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)
Study: NCT04046380

Intervention type: DIAGNOSTIC_TEST
Intervention: work of breath measurement and calculation
Description: The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.

Intervention type: DIAGNOSTIC_TEST
Intervention: work of breath measurement and calculation
Description: The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
Study: NCT02187874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT01653405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted behavioral intervention
Description: The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
Study: NCT03824028

Intervention type: DEVICE
Intervention: Clareon® IOL AutonoMe™ automated preloaded delivery system
Description: Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
Study: NCT01680549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
Study: NCT02547714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
Study: NCT03361579

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: c.p. intervention description

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: c.p. intervention description
Study: NCT03915522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single adductor canal block
Description: The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Simulated adductor canal block
Description: The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
Study: NCT02990156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil Embolization System
Description: deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotrol device from Medronic
Description: Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
Study: NCT01094639

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling root planing
Description: Deep gum cleaning with local anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supragingival Prophylaxis
Description: Plaque removal
Study: NCT00586729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vashe
Description: Antimicrobial irrigant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mafenide acetate
Description: Antimicrobial solution
Study: NCT01231308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y-Gastric Bypass
Description: Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle modification and Optimal medical Therapy
Description: Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
Study: NCT05933070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INKmune
Description: INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.
Study: NCT01515540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: 5% lidoderm patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05272215

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)

Intervention type: PROCEDURE
Intervention: Body contouring surgery
Description: Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
Study: NCT04643457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
Study: NCT02761122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy
Study: NCT04506918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR survey
Description: Participants will receive an IVR survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS survey
Description: Participants will receive a SMS survey
Study: NCT03660787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroguard
Description: Seroguard 0.41 g/L solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroguard
Description: Seroguard 0.41 g/L solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Study: NCT00402883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 week 1, 4, 16, 19 and 22.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin B12
Description: 1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5 administered intravenously weeks 1 and 4.
Study: NCT01190384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Couscous plus fiber
Description: Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: 300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean Soup
Description: Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
Study: NCT02973126

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FFRct and SPECT
Description: enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
Study: NCT00514072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prostate cancer vaccine ONY-P1
Description: given intradermally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given intradermally
Study: NCT03093090

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 6 oz
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Study: NCT04493619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV injection, 5 mg•min/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV injection, 5 mg•min/mL
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325